Laser-Based Therapy Approaches in the Retina: A Review of Micropulse Laser Therapy for Diabetic Retinopathy.

IF 0.8 4区医学 Q4 OPHTHALMOLOGY Klinische Monatsblatter fur Augenheilkunde Pub Date : 2024-11-01 Epub Date: 2024-10-10 DOI:10.1055/a-2418-5173

Ines Nagel, Arthur Mueller, William R Freeman, Igor Kozak

{"title":"Laser-Based Therapy Approaches in the Retina: A Review of Micropulse Laser Therapy for Diabetic Retinopathy.","authors":"Ines Nagel, Arthur Mueller, William R Freeman, Igor Kozak","doi":"10.1055/a-2418-5173","DOIUrl":null,"url":null,"abstract":"Purpose: This review aims to elucidate the mechanisms and clinical utility of subthreshold micropulse laser (SML) therapy in the context of retinal care. Subthreshold or \"nondestructive\" laser therapy encompasses treatment modalities that induce minimal or no harm to retinal or choroidal tissue and leave no visible sings post-application, while achieving clinical efficacy.Methods: A comprehensive review of literature sourced from databases including PubMed, Medline, Embase, Cochrane, and Web of Science was conducted, focusing on articles published before February 2024, and discussing the contemporary use of SML therapy in treating diabetic retinopathy (DR).Results: The review presents evidence from scientific literature supporting SML therapy as a viable therapeutic approach for management of DR. Across numerous studies, SML therapy has demonstrated safety and additional therapeutic efficacy without causing damage to underlying retinal tissue.Conclusion: Subthreshold laser treatment emerges as a safe strategy for addressing DR. Numerous studies have shown its additional efficacy to anti-VEGF pharmacotherapy, which is the currently approved monotherapy for complications of DR. Ongoing research and clinical investigations aim to further elucidate the mechanisms and optimize the therapeutic advantages of this technology.","PeriodicalId":17904,"journal":{"name":"Klinische Monatsblatter fur Augenheilkunde","volume":" ","pages":"1201-1206"},"PeriodicalIF":0.8000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinische Monatsblatter fur Augenheilkunde","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2418-5173","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/10 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This review aims to elucidate the mechanisms and clinical utility of subthreshold micropulse laser (SML) therapy in the context of retinal care. Subthreshold or "nondestructive" laser therapy encompasses treatment modalities that induce minimal or no harm to retinal or choroidal tissue and leave no visible sings post-application, while achieving clinical efficacy.

Methods: A comprehensive review of literature sourced from databases including PubMed, Medline, Embase, Cochrane, and Web of Science was conducted, focusing on articles published before February 2024, and discussing the contemporary use of SML therapy in treating diabetic retinopathy (DR).

Results: The review presents evidence from scientific literature supporting SML therapy as a viable therapeutic approach for management of DR. Across numerous studies, SML therapy has demonstrated safety and additional therapeutic efficacy without causing damage to underlying retinal tissue.

Conclusion: Subthreshold laser treatment emerges as a safe strategy for addressing DR. Numerous studies have shown its additional efficacy to anti-VEGF pharmacotherapy, which is the currently approved monotherapy for complications of DR. Ongoing research and clinical investigations aim to further elucidate the mechanisms and optimize the therapeutic advantages of this technology.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

视网膜激光治疗方法：微脉冲激光治疗糖尿病视网膜病变综述。

目的：本综述旨在阐明阈下微脉冲激光（SML）疗法在视网膜护理方面的机制和临床效用。阈下或 "无损 "激光疗法包括对视网膜或脉络膜组织造成最小伤害或无伤害的治疗方式，并且在应用后不会留下明显疤痕，同时还能达到临床疗效：方法：对PubMed、Medline、Embase、Cochrane和Web of Science等数据库中的文献进行了全面综述，重点关注2024年2月之前发表的文章，并讨论了SML疗法在治疗糖尿病视网膜病变（DR）中的当代应用：结果：综述介绍了科学文献中支持 SML疗法作为治疗糖尿病视网膜病变的可行疗法的证据。在众多研究中，SML疗法已证明其安全性和额外疗效，且不会对视网膜下组织造成损伤：结论：阈下激光治疗是治疗 DR 的一种安全策略。大量研究表明，阈下激光疗法比抗血管内皮生长因子药物疗法更具疗效，而抗血管内皮生长因子药物疗法是目前获准用于治疗 DR 并发症的单一疗法。目前正在进行的研究和临床调查旨在进一步阐明该技术的机制并优化其治疗优势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Klinische Monatsblatter fur Augenheilkunde 医学-眼科学

CiteScore

1.30

自引率

0.00%

发文量

235

审稿时长

4-8 weeks

期刊介绍： -Konzentriertes Fachwissen aus Klinik und Praxis: Die entscheidenden Ergebnisse der internationalen Forschung - für Sie auf den Punkt gebracht und kritisch kommentiert, Übersichtsarbeiten zu den maßgeblichen Themen der täglichen Praxis, Top informiert - breite klinische Berichterstattung. -CME-Punkte sammeln mit dem Refresher: Effiziente, CME-zertifizierte Fortbildung, mit dem Refresher, 3 CME-Punkte pro Ausgabe - bis zu 36 CME-Punkte im Jahr!. -Aktuelle Rubriken mit echtem Nutzwert: Kurzreferate zu den wichtigsten Artikeln internationaler Zeitschriften, Schwerpunktthema in jedem Heft: Ausführliche Übersichtsarbeiten zu den wichtigsten Themen der Ophthalmologie – so behalten Sie das gesamte Fach im Blick!, Originalien mit den neuesten Entwicklungen, Übersichten zu den relevanten Themen.